Observational prospective study (n=200) using computer tasks, MEG/EEG and MRI to assess how serotonergic psychedelics (psilocybin, DMT, LSD, etc.) alter brain information processing in people receiving these compounds through Yale clinical trials.
This prospective observational study will measure changes in how the brain represents and uses new versus previously learned information before, during, and after administration of serotonergic psychedelics given in parent clinical trials at Yale.
Assessments include 3–4 online computer games and questionnaires, MEG or EEG (eyes closed and evoked responses), and structural MRI at baseline, acute (day of), 1 day, 5–14 days, and 4–6 week follow-ups; semi-structured qualitative interviews may also be performed.
Participants may be in active or placebo arms of parent trials; analyses will compare psychedelic versus placebo conditions and explore whether neural processing changes predict therapeutic benefit or psychotic‑like side effects.
Participants receiving a serotonergic psychedelic as part of a Yale clinical trial (various compounds and routes).
Includes psilocybin, DMT, LSD, 5‑MeO‑DMT, ayahuasca etc.; dosing and route per parent trial; measures taken before, during, and after administration.
Participants receiving placebo as part of a parent trial.
Matched placebo (eg. diphenhydramine, saline, niacin) per parent trial.